Headline: The PDGFRɑ-inhibitor olaratumab failed to improve survival among the 509 patients with unresectable and/or metastatic soft tissue sarcoma enrolled on the phase 3 ANNOUNCE trial. In fact, median progression-free survival was significantly worse with olaratumab (5 months) versus placebo (7 months).
TBL: As feared, the PDGFRɑ-inhibitor olaratumab isn’t the long awaited savior for soft-tissue sarcoma. | Tap, ASCO 2019


Popular Posts